Sierra Oncology, Inc. Common Stock
SRRA
SRRA was delisted on the 30th of June, 2022.
59 hedge funds and large institutions have $81.2M invested in Sierra Oncology, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 18 reducing their positions, and 9 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
27% more capital invested
Capital invested by funds: $64M → $81.2M (+$17.2M)
3% less funds holding
Funds holding: 61 → 59 (-2)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
50% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$366K |
| 2 |
6CM
683 Capital Management
New York
|
+$224K |
| 3 |
TI
Telemetry Investments
New York
|
+$188K |
| 4 |
Renaissance Technologies
New York
|
+$139K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$127K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$792K |
| 2 |
AG
Algert Global
San Francisco,
California
|
-$431K |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$341K |
| 4 |
O
OrbiMed
New York
|
-$160K |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
-$154K |
SRRA Hedge Fund Activity: Q1 2019 in Review
59 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q1 2019, worth a combined $81.2M — up 27% from $64M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of SRRA and 7 opened new positions — a net loss of 2 holders — while 18 trimmed existing stakes and 9 added.
The largest buyer was Bridgeway Capital Management, adding an estimated $366K. The largest seller was Citadel Advisors, cutting an estimated $792K.
- 59 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q1 2019, down from 61 in Q4 2018.
- Funds reported $81.2M of Sierra Oncology, Inc. Common Stock stock for Q1 2019, up 27% quarter-over-quarter.
- 7 funds opened new Sierra Oncology, Inc. Common Stock positions in Q1 2019 and 9 closed out, a net change of -2 holders.
- The largest Sierra Oncology, Inc. Common Stock buyer in Q1 2019 was Bridgeway Capital Management, an estimated $366K added.
- The largest Sierra Oncology, Inc. Common Stock seller in Q1 2019 was Citadel Advisors, an estimated $792K sold.
Based on aggregated 13F filings for Q1 2019.